Ketamine but not glycine potentiates antidepressant like action of citalopram in mice exposed to chronic mild stress
Keywords:NMDA, Ketamine, Citalopram, Glycine, Depression
Background: The present study was designed to investigate the effect of citalopram, ketamine, glycine and their combinations on animal models of depression.
Methods: Swiss Albino male mice were subjected to chronic mild stress for 6 weeks for inducing depression, and randomly divided into different groups: citalopram (5 and 10 mg/kg), ketamine (17.5 and 35 mg/kg), glycine (50 and 100 mg/kg), ketamine (17.5 mg/kg) + citalopram (5 mg/kg) and ketamine (17.5 mg/kg) + glycine (50 mg/kg). Two behavioural tests were utilized for the assessment of depression, namely tail suspension test (TST) and forced swim test (FST). Immobility time was recorded for 6 min, before and after administration of drug.
Results: Citalopram (10 mg/kg) administration caused significant decrease in the immobility time in TST model only but not in FST. Citalopram (5 mg/kg) and ketamine (17.5 mg/kg) caused insignificant decrease in immobility time in both the models. Moreover, ketamine in combination with Citalopram significantly reduced the immobility time in both the models. Glycine at a dose of 100 mg/kg (but not 50 mg/kg) significantly increased the immobility time in both the models as compared to control group. Further, ketamine when administered with glycine caused increase in the immobility time on both the paradigms, though insignificant.
Conclusions: Ketamine demonstrated antidepressant like action in both TST and FST models. Moreover, it potentiated the antidepressant effect of citalopram that might be due to the role of NMDA receptors.
Gerhard DM, Wohleb ES, Duman RS. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. Drug Discov Today. 2016;21:45464.
Hindmarch I. Expanding the horizons of depression beyond the monoamine hypothesis. Hum Psychopharmacol. 2001;16:20318.
Schwartz J, Murrough JW, Iosifescu DV. Ketamine for treatment resistant depression recent developments and clinical applications. Evid Based Mental Health. 2016;19:358.
Brunton L, Chabner B, Knollman B. Goodman and Gilman's The pharmacological basis of therapeutics. 13th ed. New York: Tata McGraw-Hill Education; 2017:397-416.
Szewczyk B, Pałucha-Poniewiera A, Poleszak E, Pilc A, Nowak G. Investigational NMDA receptor modulators for depression. Expert Opin Investig Drugs. 2012;21:91-102.
Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856-64.
Zanos P, Moaddel R, Morris PJ. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481-6.
Yang C, Shirayama Y, Zhang JC. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Translational Psychiatr. 2015;5:e632.
Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatr. 2015;172:950-66.
Moaddel R, Abdrakhmanova G, Kozak J. Sub-anesthetic concentrations of (R, S)-ketamine metabolites inhibit acetylcholine evoked currents in alpha7 nicotinic acetylcholine receptors. Eur J Pharmacol. 2013;698:228-34.
Schweizer MC, Henniger MS, Sillaber I. Chronic mild stress in mice: of anhedonia, ‘anomalous anxiolysis’ and activity. PloS One. 2009;4(1):e4326.
Mombereau C, Gur TL, Onksen J, Blendy JA. Differential effect of acute and repeated citalopram in mouse model of anxiety and depression. Int J Neuropsychopharmacol. 2010;13(3):321-34.
Porsolt RD. Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977;266:730-2.
Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology. 1985; 85(3):367-70.
Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 2005;29:571-625.
Antoniuk S, Bijata M, Ponimaskin E, Wlodarczyk, J. Chronic unpredictable mild stress for modeling depression in rodents: meta-analysis of model reliability. Neurosci Biobehav Rev. 2019;99:101-16.
Araujo SM, Poetini MR, Bortolotto VC, de Freitas Couto S, Pinheiro FC, Meichtry LB, et al. Chronic unpredictable mild stress-induced depressive-like behavior and dysregulation of brain levels of biogenic amines in Drosophila melanogaster. Behav Brain Res. 2018;351:104-13.
Castagné V, Moser P, Roux S, Porsolt RD. Rodent models of depression: forced swim and tail suspension behavioural despair tests in rats and mice. Curr Protoc Neurosci. 2011;8:10.
Sánchez C, Meier E. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology. 1997;129(3): 197-205.
Dulawa SC, Holick KA, Gundersen B, Hen R. Effects of Chronic Fluoxetine in Animal Models of Anxiety and Depression. Neuropsychopharmacology. 2004;29: 1321-30.
Cryan JF, Page ME, Lucki I. Differential behavioral effect of the antidepressant reboxtine, fluoxetine and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology. 2005;182(3): 335-44.
Chaturvedi HK, Chandra D, Bapna JS. Effect of NMDA receptor antagonists in forced swimming test and its modification by antidepressants. Indian J Physiol Pharmacol. 1999;31:104-9.
Réus GZ, Stringari RB, Kirsch TR, Fries GR, Kapczinski F, Roesler R, et al. Neurochemical and behavioural effects of acute and chronic memantine administration in rats: Further support for NMDA as a new pharmacological target for the treatment of depression? Brain Res Bull. 2010;81:585-9.
Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91-5.
Mathew JS, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, et al. Ketamine for Treatment-Resistant Unipolar Depression. CNS Drugs. 2012;26(3):189-204.
Rogoz Z, Skuza G, Maj J, Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology. 2002;42:1024-30.
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-4.
Lindefors N, Barati S, O’Connor. WTO: Differential effect of single and repeated ketamine administration on dopamine, serotonin, and GABA transmission in rat medial prefrontal cortex. Brain Res. 1997;759:205-12.
Elliot K, Kest B, Man A, Kao B, Inturrisi CE. N-Methyl-D-Aspartate (NMDA) receptors, µ and κ opiod tolerance, and perspective on new analgesic drug development. Neuropsycopharmacology. 1995;13: 347-56.
Wong CS, Cherng CH, Luk HN, Ho ST, Tung CS. Effect of NMDA receptor antagonist on inhibition of morphine tolerance in rats: Binding at µ-opioid receptors. Eur J Pharmacol. 1996;297:27-33.
Burgdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK, et al. GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects. Neuropsycho-pharmacology. 2013;38(5):729-42.
Zhu WL, Wang SJ, Liu MM, Shi HS, Zhang RX, Liu JF, et al. Glycine site N-methyl-D aspartate receptor antagonist 7-CTKA produces rapid antidepressant-like effects in male rats. J Psychiatry Neurosci. 2013; 38(5):306-16.